Burning Rock Biotech (BNR) Current Deferred Revenue (2019 - 2026)

Burning Rock Biotech's Current Deferred Revenue history runs 8 years deep, the most recent figure standing at $16.6 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue rose 2.76% year-over-year to $16.6 million; the TTM figure through Mar 2026 stood at $16.6 million (up 2.76% YoY), while the FY2025 annual figure was $15.4 million, down 4.54% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $16.6 million, up from $15.2 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $25.1 million in Q1 2022, with the low at $14.4 million in Q2 2025.
• The 5-year median for Current Deferred Revenue is $17.7 million (2024), against an average of $18.7 million.
• The sharpest annual moves came in 2022 and 2024: Current Deferred Revenue surged 80.57% in 2022, then declined 21.4% in 2024.
• Burning Rock Biotech's Current Deferred Revenue stood at $20.8 million in 2022, then decreased by 12.66% to $18.1 million in 2023, then slipped by 9.47% to $16.4 million in 2024, then declined by 7.38% to $15.2 million in 2025, then grew by 9.18% to $16.6 million in 2026.
• Business Quant data shows BNR's Current Deferred Revenue at $16.6 million in Q1 2026, $15.2 million in Q4 2025, and $15.0 million in Q3 2025.